Bristol-Myers Squibb (Bristol), a leading pharmaceutical company, has announced its plans to acquire cancer drugmaker Mirati Therapeutics for a staggering $5.8 billion. The acquisition comes as Bristol aims to diversify its oncology business and counter the anticipated revenue loss from upcoming patent expirations.
Mirati Therapeutics has an impressive portfolio of drugs that specifically target genetic drivers of various types of cancers. One of their remarkable achievements includes the approval of their lung cancer drug, Krazati, just last December. Bristol executives have particularly emphasized the potential of Mirati’s second compound, MRTX1719, in treating specific types of lung cancer. This acquisition presents Bristol with an opportunity to expand its reach in the highly lucrative field of cancer therapeutics.
To fund this deal, Bristol plans to utilize a combination of cash and debt. The company will pay $4.8 billion in cash, with an additional value opportunity of $1 billion for Mirati stockholders. Bristol’s major motivation for this acquisition lies in the strategic advantage it offers in strengthening their diversified oncology portfolio. With the declining demand for its top drugs, Revlimid and Eliquis, Bristol urgently needs to find new revenue sources and the acquisition of Mirati Therapeutics seems to be the way forward.
Interestingly, Mirati’s shares are currently trading below their 52-week high, making the deal more economical for Bristol. This cost-effectiveness combined with the potential growth prospects of Mirati’s drugs have further intensified Bristol’s interest in the acquisition.
However, it is worth noting that this transaction may have a dilutive impact on Bristol’s non-GAAP earnings per share by approximately 35 cents in the first year. Despite this temporary setback, Bristol remains confident in the long-term benefits of this acquisition and the positive impact it will have on their overall business strategy.
Adding to the significance of this announcement is the impending departure of Bristol’s CEO, Giovanni Caforio, in November. He will be succeeded by Chris Boerner, who has expressed support for the acquisition. This change in leadership further underscores the strategic nature of this move and Bristol’s commitment to expanding its presence in the oncology sector.
Overall, the acquisition of Mirati Therapeutics by Bristol-Myers Squibb is expected to have far-reaching implications in the pharmaceutical industry. Bristol’s bold move to strengthen its oncology portfolio and counter upcoming patent expirations demonstrates their determination to remain at the forefront of cancer drug development, ensuring that they continue to make a significant impact in patients’ lives.
“Prone to fits of apathy. Devoted music geek. Troublemaker. Typical analyst. Alcohol practitioner. Food junkie. Passionate tv fan. Web expert.”